In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Muriel Aline SpahnRadiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-9629-8662 Tom Van LoyMolecular Structural and Translational Virology Research Group, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-2524-7264 Christophe M DerooseNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-6080-1577 Sofie CelenDepartment of Nuclear Medicine, University Hospitals UZ Leuven, 3000 Leuven, Belgium.
Dominique ScholsMolecular Structural and Translational Virology Research Group, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-3256-5850 Guy BormansRadiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-0335-7190 Janke KleynhansDepartment of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, 11519 Prague, Czech Republic.ORCID 0000-0001-9393-8855 Frederik CleerenMolecular Structural and Translational Virology Research Group, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-3692-1608 Funding
KU Leuven C14/21/111Stichting tegen Kanker C/2020/1528
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
auger emissionCXCR4positron emission tomography (PET)targeted radionuclide therapy (TRNT)terbium-161theranostics
Identifiers
PMID42653659
PMCPMC13516207
What OpenQuestion holds
Textmetadata
Read underepoch 390